DiscoverCME in Minutes: Education in Oncology & Hematology
CME in Minutes: Education in Oncology & Hematology
Claim Ownership

CME in Minutes: Education in Oncology & Hematology

Author: Answers in CME

Subscribed: 16Played: 281
Share
© 2022

Description

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
161 Episodes
Reverse
Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

2025-10-1501:05:40

Please visit answersincme.com/860/240201301-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss how the latest evidence on frontline immunotherapy-based regimens can be integrated into practice to optimize outcomes for patients with advanced NSCLC. Upon completion of this activity, participants should be better able to: Review the latest data on frontline immunotherapy-based regimens for the treatment of advanced NSCLC; Identify patient-, disease-, and drug-related factors that may inform the frontline use of immunotherapy-based regimens for advanced NSCLC; and Outline evidence-based, multidisciplinary strategies to optimize long-term patient outcomes with frontline immunotherapy-based regimens in advanced NSCLC.
Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

2025-10-0321:30

Please visit answersincme.com/MPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myelodysplastic syndromes discusses strategies for the management of FLT3-mutated acute myeloid leukemia. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML); Recognize the clinical significance of the evidence for approved FLT3 inhibitors in the first-line treatment of newly diagnosed, FLT3-mutated AML; Formulate strategies to maximize the impact of FLT3 inhibitors in the management of patients with newly-diagnosed, FLT3-mutated AML.
Justin F. Gainor, MD - A Blueprint for Action: Integrating Pre- and/or Post-Operative Immunotherapy Into Early-Stage NSCLC Management

Justin F. Gainor, MD - A Blueprint for Action: Integrating Pre- and/or Post-Operative Immunotherapy Into Early-Stage NSCLC Management

2025-09-3052:42

Please visit answersincme.com/860/99485655-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) use a case-based approach to explore evidence-based strategies to optimize early-stage, resectable NSCLC care with (neo)adjuvant/perioperative immunotherapy, highlighting the role of multidisciplinary teams. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the (neo)adjuvant/perioperative treatment of patients with early-stage, resectable NSCLC; Formulate strategies to appropriately integrate immunotherapy-based (neo)adjuvant/perioperative regimens into treatment plans for patients with early-stage, resectable NSCLC; Discuss multidisciplinary team approaches to enhance care for patients with early-stage, resectable NSCLC.
Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

2025-09-3019:38

Please visit answersincme.com/UDT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses primary chemoimmunotherapy regimens in advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Apply biomarker testing results to guide initial treatment decisions in advanced endometrial cancer; Select the optimal therapy for a given patient with endometrial cancer, based on the latest evidence; Design patient-centered, multidisciplinary care plans that support treatment continuity and patient survivorship.
Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

2025-09-3017:51

Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.
Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach

Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach

2025-09-2401:03:32

Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.
Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

2025-09-2215:59

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.
David Rees, MA, MBBS, FRCPath, FRCPCH, FRCP - Sickle Cell Disease in Perspective: An Expert Point of View on Therapeutic Selection and Comprehensive Care

David Rees, MA, MBBS, FRCPath, FRCPCH, FRCP - Sickle Cell Disease in Perspective: An Expert Point of View on Therapeutic Selection and Comprehensive Care

2025-09-1215:26

Please visit answersincme.com/GTM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in sickle cell disease discusses comprehensive therapeutic selection strategies, from disease-modifying therapies to gene therapy options, and evidence-based approaches for optimizing patient outcomes across the disease spectrum. Upon completion of this activity, participants should be better able to: Review the impact that disease manifestations such as vaso-occlusive crises have on patients with sickle cell disease; Assess the efficacy and safety of available therapies for sickle cell disease and their implications for clinical practice; and Apply evidence-based strategies to optimize treatment outcomes in patients with severe sickle cell disease.
Mona Shafey, MD, FRCPC / Nicole Lamanna, MD - Charting the Course: Navigating the Maze of Treatment Selection and Sequencing in CLL

Mona Shafey, MD, FRCPC / Nicole Lamanna, MD - Charting the Course: Navigating the Maze of Treatment Selection and Sequencing in CLL

2025-09-1201:06:39

Please visit answersincme.com/860/240201294-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss how to select and sequence treatments for patients with CLL. Upon completion of this activity, participants should be better able to: Review guideline recommendations for preferred treatments in patients with CLL; Identify the clinical implications of the latest evidence informing the use of second-generation BTK inhibitors in patients with CLL; Outline practical strategies to optimize outcomes with second-generation BTK inhibitors in patients with CLL; and Describe emerging therapeutic agents currently under investigation for the treatment of CLL.
Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

2025-09-1055:02

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.
Jesus Berdeja, MD - Chartering New Frontiers in Myeloma Care: What Role May Novel CELMoDs Play in Early-Relapse Therapy?

Jesus Berdeja, MD - Chartering New Frontiers in Myeloma Care: What Role May Novel CELMoDs Play in Early-Relapse Therapy?

2025-08-1817:42

Please visit answersincme.com/NPK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma (MM) answers common questions about incorporating novel cereblon E3 ligase modulators (CELMoDs) in early-relapse therapy for patients with MM. Upon completion of this activity, participants should be better able to: Identify the rationale for incorporating novel CELMoDs in early-relapse therapy in patients with MM; Discuss the clinical impact of the latest data for emerging novel CELMoDs in the early-relapse setting for patients with MM; and Describe potential considerations for integrating novel CELMoDs in the treatment landscape of MM as they become available.
Sebastian Stintzing, MD - A Step-by-Step Guide to Metastatic CRC: Strategies to Integrate Anti-EGFR Therapies

Sebastian Stintzing, MD - A Step-by-Step Guide to Metastatic CRC: Strategies to Integrate Anti-EGFR Therapies

2025-08-1321:46

Please visit answersincme.com/FAH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancer discusses strategies to integrate anti-EGFR therapies into the treatment of metastatic colorectal cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of the latest evidence for anti-EGFR-based regimens for patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC); Outline strategies to optimize the integration of anti-EGFR-based regimens into management plans for patients with RAS/BRAF wild-type mCRC; and Review guideline recommendations for the management of RAS/BRAF wild-type mCRC.
Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation

Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation

2025-07-3119:40

Please visit answersincme.com/HSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in urothelial cancer discusses biomarker testing for patients with locally advanced/metastatic urothelial cancer. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes with novel approved therapies in locally advanced/metastatic UC (LA/mUC); Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following the identification of actionable biomarkers.
Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC

Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC

2025-07-2915:08

Please visit answersincme.com/PYP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses TROP2-directed antibody-drug conjugates (ADCs) for the treatment of patients with advanced, pretreated EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Identify the rationale for using TROP2-directed ADCs in the treatment of patients with advanced, pretreated EGFR-mutated NSCLC; Review clinical evidence on emerging TROP2-directed ADCs in patients with advanced, pretreated EGFR-mutated NSCLC; and Outline evidence-based strategies to incorporate TROP2-directed ADCs for patients with advanced, pretreated EGFR-mutated NSCLC.
Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World

Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World

2025-07-2828:17

Please visit answersincme.com/860/97851223-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the practical application of immunotherapy-based regimens for the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.
John Marshall, MD - Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors

John Marshall, MD - Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors

2025-07-1822:43

Please visit answersincme.com/KTK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancers discusses strategies for treatment of patients with colorectal cancer using tyrosine kinase inhibitors. Upon completion of this activity, participants should be better able to: Identify patients with metastatic colorectal cancer (mCRC) who are suitable for tyrosine kinase inhibitor (TKI) treatment; Outline practical, patient-centered strategies to maximize quality of life in patients receiving later-line TKI treatment for mCRC; and Review approaches to manage adverse events associated with later-line TKI treatment for mCRC.
Neil D. Gross, MD, FACS - Evolving the Multi-Modal Approach for Resectable Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Assessment of Current and Emerging Immunotherapeutic Strategies

Neil D. Gross, MD, FACS - Evolving the Multi-Modal Approach for Resectable Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Assessment of Current and Emerging Immunotherapeutic Strategies

2025-07-1101:09:29

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.
Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

2025-07-0723:00

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.
Selim Corbacioglu, MD, PhD - Transforming Transfusion Dependence: Practical Steps for Incorporating Novel Beta Thalassemia Treatments Into Practice

Selim Corbacioglu, MD, PhD - Transforming Transfusion Dependence: Practical Steps for Incorporating Novel Beta Thalassemia Treatments Into Practice

2025-07-0415:55

Please visit answersincme.com/BUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the latest treatments for transfusion-dependent beta thalassemia (TDT). Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the efficacy and safety data for novel TDT therapies; Identify appropriate patients for novel TDT therapies; and Apply strategies to integrate novel TDT therapies into real-world clinical practice.
Thomas Powles, MBBS, MRCP, MD / Jonathan E. Rosenberg, MD - Advancing Urothelial Carcinoma Care With Multidisciplinary Strategies for Clinical Management

Thomas Powles, MBBS, MRCP, MD / Jonathan E. Rosenberg, MD - Advancing Urothelial Carcinoma Care With Multidisciplinary Strategies for Clinical Management

2025-07-0301:07:37

Please visit answersincme.com/WHF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss how the latest therapeutic advances in frontline management of urothelial carcinoma can be integrated into practice to optimize patient care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the first-line treatment of advanced UC; Identify multidisciplinary strategies to optimize first-line treatment of patients with advanced UC; and Outline current and evolving multidisciplinary approaches to enhance outcomes for patients with UC.
loading
Comments 
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States